Therapeutic Apheresis and Dialysis

(The H4-Index of Therapeutic Apheresis and Dialysis is 12. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-06-01 to 2024-06-01.)
COVID‐19 of dialysis patients in Japan: Current status and guidance on preventive measures47
The Japanese Society for Apheresis clinical practice guideline for therapeutic apheresis29
Double filtration plasmapheresis: Review of current clinical applications26
Vadadustat for anemia in chronic kidney disease patients on peritoneal dialysis: A phase 3 open‐label study in Japan18
The scientific basis and future of lipoprotein apheresis16
Performance, clinical effectiveness, and safety of immunoadsorption in a wide range of indications15
Assessment of the accuracy of an intermittent‐scanning continuous glucose monitoring device in patients with type 2 diabetes mellitus undergoing hemodialysis (AIDT2H) study15
A COVID‐19 pandemic‐specific, structured care process for peritoneal dialysis patients facilitated by telemedicine: Therapy continuity, prevention, and complications management14
Super high‐flux hemodialysis provides comparable effectiveness with high‐volume postdilution online hemodiafiltration in removing protein‐bound and middle‐molecule uremic toxins:13
Application of plasmapheresis for Covid‐19 patients13
Potential limitations of plasmapheresis in treatment of COVID‐19 patients: How to overcome them?12
Effectiveness of SARS‐CoV‐2 vaccines on hemodialysis patients in Japan: A nationwide cohort study12
Two long‐term phase 3 studies of enarodustat (JTZ‐951) in Japanese anemic patients with chronic kidney disease not on dialysis or on maintenance hemodialysis: SYMPHONY ND‐Long an12
Extracorporeal blood purification is associated with improvement in biochemical and clinical variables in the critically‐ill COVID‐19 patients12